Literature DB >> 7134994

Radiation treatment of carcinoma of the cervix.

T L Thar, R R Million, J W Daly.   

Abstract

To give the optimal treatment to each individual with cancer of the cervix, there must be very close cooperation and professional rapport between the radiation oncologist and gynecologic oncologist. Patients should be evaluated together with a review of the pertinent pathology and diagnostic roentgenograms in order to determine the optimal, individualized treatment plan for each patient. In the radiotherapeutic management of patients with cervical cancer, meticulous care must be taken in the treatment setups for external radiotherapy and the intracavitary radium applications. External fields should be carefully shaped to minimize the amount of normal tissue treated. Radium applications must be carefully reviewed with attention to and correction of minor deviations in the radium geometry, which could give rise to "hot" or "cold" spots in the radium dosage. With attention paid to the above factors, radiotherapy in the treatment of cervical cancer can be extremely rewarding. The majority of the patients treated will be cured and will be able to return to normal, functional lives. Most of the patients seen with cervical cancer do not have other major medical illnesses that will limit their lifespan, and as a result, 10-, 20-, and 30-yr survivals after treatment are being reported.

Entities:  

Mesh:

Year:  1982        PMID: 7134994

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  3 in total

1.  Neoadjuvant bleomycin, ifosfamide and cisplatin in cervical cancer.

Authors:  J Tobias; E J Buxton; G Blackledge; J J Mould; J Monaghan; D Spooner; A Chetiyawardana
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up.

Authors:  Daniela Luvero; Francesco Plotti; Alessia Aloisi; Stella Capriglione; Roberto Ricciardi; Andrea Miranda; Salvatore Lopez; Giuseppe Scaletta; Giovanna De Luca; Pierluigi Benedetti-Panici; Roberto Angioli
Journal:  Med Oncol       Date:  2016-08-30       Impact factor: 3.064

3.  Cisplatin-ifosfamide as neoadjuvant chemotherapy in stage IIIB cervical uterine squamous-cell carcinoma.

Authors:  P C Lara; J L Garcia-Puche; V Pedraza
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.